Exagen Inc - ESG Rating & Company Profile powered by AI
Scroll down to the bottom of the webpage for potential risks for Exagen Inc based on industry, geography and size. This ESG rating covers seventeen UN Sustainable Development Goals including: 'Zero Hunger', 'Sustainable Cities & Communities' and 'Life on Land'. The webpage is a zero-cost E,S&G report covering Exagen Inc.
Exagen Inc in the Biotechnology & Medical Research industry gained a UN SDG ESG Transparency Score of 0.7; made up of an environmental score of 0.0, social score of 0.0 and governance score of 2.0.
0.7
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Analytik Jena AG | 8.0 | High |
| 1 | Amniotics AB (publ) | 8.0 | High |
| ... | ... | ... | |
| 162 | Solegreen Ltd | 0.9 | Low |
| 178 | Peijia Medical Ltd | 0.8 | Low |
| 179 | Exagen Inc | 0.7 | Low |
| 179 | Check Cap Ltd | 0.7 | Low |
| 179 | Mertiva AB | 0.7 | Low |
| 182 | Wesana Health Holdings Inc | 0.0 | Low |
| 182 | rEVO Biologics Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Exagen Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Exagen Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Exagen Inc report the average age of the workforce?
Sign up for free to unlockDoes Exagen Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Exagen Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Exagen Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Exagen Inc offer flexible work?
Sign up for free to unlockDoes Exagen Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Exagen Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Exagen Inc conduct supply chain audits?
Sign up for free to unlockDoes Exagen Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Exagen Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Exagen Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Exagen Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Exagen Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Exagen Inc disclose water use targets?
Sign up for free to unlockDoes Exagen Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Exagen Inc have a product recall in the last two years?
Sign up for free to unlockDoes Exagen Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Exagen Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Exagen Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Exagen Inc disclose parental leave metrics?
Sign up for free to unlockDoes Exagen Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Exagen Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Exagen Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Exagen Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Exagen Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Exagen Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Exagen Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Exagen Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Exagen Inc disclose its waste policy?
Sign up for free to unlockDoes Exagen Inc report according to TCFD requirements?
Sign up for free to unlockDoes Exagen Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Exagen Inc disclose energy use targets?
Sign up for free to unlockDoes Exagen Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Exagen Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Exagen Inc
These potential risks are based on the size, segment and geographies of the company.
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.